Skip to main content Accessibility help

Is there a role of adjuvant treatment for salivary duct carcinoma?

  • T Nakashima (a1), R Yasumatsu (a1), S Toh (a1), K Hashimoto (a1), M Shinoto (a2), K Nakamura (a2) and S Komune (a1)...



To determine the clinical effect of post-operative radiotheraphy and systemic chemotherapy for the treatment of salivary duct carcinoma.

Study design:

Retrospective review.


The medical records of 26 patients treated by surgery with or without radiotheraphy and/or systemic chemotherapy for salivary duct carcinoma were retrospectively reviewed to investigate the role of post-operative adjuvant treatment for the patients' prognosis.


The overall three-year and five-year survival rates were 54 and 48.1 per cent, respectively. There was no correlation with the clinical stage and the patients' prognosis. The overall three-year survival of the patients with or without post-operative radiotheraphy was 64 and 33 per cent, respectively (p = 0.29). The overall three-year survival of the patients with or without post-operative chemotherapy was 53 and 56 per cent, respectively (p = 0.78).


Post-operative adjuvant therapy did not improve the patients' overall prognosis with salivary duct carcinoma. Developing novel treatment modalities may be necessary to improve the prognosis of this aggressive disease.


Corresponding author

Address for correspondence: T Nakashima, Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan E-mail:


Hide All
1Guzzo, M, Di Palma, S, Grandi, C, Molinari, R. Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 1997;19:126–33
2Barnes, L, Rao, U, Krause, J, Contis, L, Schwartz, A, Scalamogna, P. Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol 1994;78:6473
3Jayaprakash, V, Merzianu, M, Warren, GW, Arshad, H, Hicks, WL Jr, Rigual, NR et al. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the Surveillance, Epidemiology, and End Results database. Head Neck 2014;36:694701
4Shinoto, M, Shioyama, Y, Nakamura, K, Nakashima, T, Kunitake, N, Higaki, Y et al. Postoperative radiotherapy in patients with salivary duct carcinoma: clinical outcomes and prognostic factors. J Radiat Res 2013;54:925–30
5Kim, JY, Lee, S, Cho, KJ, Kim, SY, Nam, SY, Choi, SH et al. Treatment results of post-operative radiotherapy in patients with salivary duct carcinoma of the major salivary glands. Br J Radiol 2012;85:e947–52
6Dimery, IW, Legha, SS, Shirinian, M, Hong, WK. Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol 1990;8:1056–62
7Dodd, RL, Slevin, NJ. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol 2006;42:759–69
8Lewis, JE, McKinney, BC, Weiland, LH , Ferreiro, JA , Olsen, KDSalivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 1996;77:223–30
9Krishnamurthy, J, Krishnamurty, DM, Baker, JJ, Zhen, W, Lydiatt, D, Ganti, AKSalivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature. Head Neck 2013;35:E372–5
10Jaspers, HC, Verbist, BM, Schoffelen, R, Mattijssen, V, Slootweg, PJ, van der Graaf, WT et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 2011;29:e473–6
11Masubuchi, T, Tada, Y, Maruya, SI, Osamura, Y, Kamata, SE, Miura, K et al. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol 2014; in press.
12Soper, MS, Iganej, S, Thompson, LD. Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy. Head Neck 2014;36:E47


Is there a role of adjuvant treatment for salivary duct carcinoma?

  • T Nakashima (a1), R Yasumatsu (a1), S Toh (a1), K Hashimoto (a1), M Shinoto (a2), K Nakamura (a2) and S Komune (a1)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed